42 completed. 42 Phase 1, 2 Phase 2.
By phase and status
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Trials (filtered) newest first · largest first
All 42 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
JLP-2002, Comparator - Overactive Bladder(OAB) | Phase 1 | Completed | 42 | 2021-03-13 | 2021-06-14 |
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | 32 | 2020-08-12 | 2024-03-26 |
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
BAY1817080, [14C]BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | 14 | 2020-08-05 | 2023-01-26 |
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080, Midazolam - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | 37 | 2020-07-23 | 2023-01-20 |
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder | Phase 1 | Completed | 36 | 2020-07-20 | 2020-10-28 |
Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants
BAY1817080, Moxifloxacin, Placebo - Cough, Endometriosis | Phase 1 | Completed | 42 | 2020-06-18 | 2022-01-24 |
Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder
Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox] - Overactive Bladder | Phase 1 | Completed | 38 | 2020-05-12 | 2022-04-15 |
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
BAY1817080, Matching Placebo - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | 36 | 2020-02-15 | 2023-01-26 |
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
Meditoxin, Botox - Overactive Bladder | Phase 1 | Completed | 30 | 2017-12-13 | 2019-03-27 |
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence
AHLeveeS System - Overactive Bladder | Phase 1 | Completed | 6 | 2017-08-17 | 2018-08-22 |
Mirabegron For Erectile Dysfunction
Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | 20 | 2017-08-01 | 2021-01-05 |
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
Formulation 1 solabegron, Formulation 2 solabegron - Healthy Subjects, Overactive Bladder | Phase 1 | Completed | 24 | 2016-10-01 | 2019-04-24 |
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
Dried Cranberry, Placebo Oral Capsule - Overactive Bladder | Phase 1 | Completed | 77 | 2016-04-01 | 2018-09-17 |
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
HIP1503, HGP1103 - Overactive Bladder | Phase 1 | Completed | 36 | 2016-03-01 | 2016-10-20 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
mirabegron - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Completed | 9 | 2015-12-17 | 2024-10-31 |
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg - LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia | Phase 1 | Completed | 54 | 2015-08-01 | 2016-06-24 |
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
JLP-1207(Fasted), JLP-1207(Fed) - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | 54 | 2015-07-01 | 2016-06-24 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
Mirabegron - Neurogenic Detrusor Overactivity, Overactive Bladder | Phase 1 | Completed | 34 | 2014-09-21 | 2024-10-22 |
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
Tamsulosin, Solifenacin, Tamsulosin and solifenacin - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | 36 | 2014-07-01 | 2016-06-24 |
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
Vibegron - Overactive Bladder | Phase 1 | Completed | 16 | 2013-01-15 | 2018-12-24 |
Showing 20 of 42. Sign in to see all of them.
Narrower conditions
Prostatic Hyperplasia (6) · Urinary Incontinence (4) · Erectile Dysfunction (2) · Lower Urinary Tract Symptoms (2) · Cough (1) · Endometriosis (1) · Kidney Failure, Chronic (1) · Urinary Bladder Neck Obstruction (1) · Urinary Incontinence, Urge (1)
Broader conditions
Female Urogenital Diseases (42) · Female Urogenital Diseases and Pregnancy Complications (42) · Male Urogenital Diseases (42) · Pathological Conditions, Signs and Symptoms (42) · Signs and Symptoms (42) · Urinary Bladder Diseases (42) · Urogenital Diseases (42) · Urologic Diseases (42) · Urological Manifestations (42) · Lower Urinary Tract Symptoms (40) · Genital Diseases (8) · Genital Diseases, Male (7) · Prostatic Diseases (6) · Urination Disorders (5) · Mental Disorders (2)
Interventions
mirabegron (8) · Solifenacin Succinate (6) · Tolterodine Tartrate (5) · Tamsulosin (4) · fesoterodine (4) · Botulinum Toxins, Type A (3) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (2) · Warfarin (2) · solabegron (2) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · Dimethyl Sulfoxide (1) · Ketoconazole (1) · Midazolam (1) · Moxifloxacin (1) · Pharmaceutical Preparations (1)
Sponsors
Astellas Pharma Inc (7) · Bayer (5) · Jeil Pharmaceutical Co., Ltd. (4) · Pfizer (4) · GlaxoSmithKline (3) · Merck Sharp & Dohme LLC (3) · Astellas Pharma Europe B.V. (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · Boryung Pharmaceutical Co., Ltd (1) · Hanmi Pharmaceutical Company Limited (1) · Hugel (1) · Johns Hopkins University (1) · Mayo Clinic (1) · Medy-Tox (1) · Neuspera Medical, Inc. (1)
Countries
United States (13) · South Korea (5) · Denmark (4) · Netherlands (4) · Belgium (3) · Poland (3) · Singapore (3) · Japan (2) · United Kingdom (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Norway (1) · Serbia (1)
Top investigators
Kyung-sang Yu, M.D., Ph.D. (2) · An-Hye Kim (1) · Arthur L Burnett, M.D., M.B.A. (1) · Bilal Chughtai, MD (1) · Eliot Ohlstein, PhD (1) · Gommert A. van Koeveringe (1) · Kyung-sang Yu, M.D.,Ph.D. (1)
Results publications
PMID 19648387, PMID 21905086, PMID 37160401, PMID 38044419, PMID 38907175
NIH funding
2009 (1), 2014 (1), 2015 (1)